Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 19/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 19/20 | 0.52 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28814272 | 0.82 | TAS1R3 (0.60) | TAS1R3TAS1R1 | |
| SCHEMBL453576 | 0.81 | ALDH1A1 (0.49) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL8964466 | 0.81 | ALDH1A1 (0.49) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL453575 | 0.81 | ALDH1A1 (0.49) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL810660 | 0.80 | TAS1R3 (0.68) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL8964444 | 0.77 | ALDH1A1 (0.47) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL8964517 | 0.77 | ALDH1A1 (0.47) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL810598 | 0.76 | TAS1R3 (0.82) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL11516612 | 0.75 | PLA2G2A (0.44) | TAS1R3TAS1R1 | |
| SCHEMBL9601878 | 0.75 | TAS1R3 (0.76) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |